Kymriah (tisagenlecleucel)

pCPA File Number: 22470

Negotiation Status:

Under consideration for negotiation

Indication(s):

Indicated for the treatment of adult patients with relapsed or refractory grade 1, 2, or 3a follicular lymphoma (FL) after two or more lines of systemic therapy.

Sponsor/Manufacturer:

Novartis Pharmaceuticals Canada Inc.

CADTH Project Number:

PG0306-000

pCPA Engagement Letter Issued:

Not Applicable

Negotiation Process Concluded:

Not Applicable